InnovAge Holding Earnings Call Transcripts
Fiscal Year 2026
-
The platform has evolved through significant transformation, now delivering integrated, value-based care for complex seniors with consistent financial growth and expanding margins. Long-term growth is supported by under-penetrated market opportunities, policy tailwinds, and pragmatic AI adoption. 2027 guidance targets $105–$115 million adjusted EBITDA, with a focus on sustainable margins.
-
Fiscal 2026 saw strong growth in revenue, adjusted EBITDA, and operational efficiency, with margin expansion and improved participant outcomes. Fiscal 2027 guidance targets continued census and revenue growth, disciplined margin management, and further technology-driven efficiencies. Fiscal risks include unresolved state rates and ongoing regulatory changes.
-
Q3 saw strong revenue and margin growth, driven by higher capitation rates and improved operational execution, despite a net loss from increased litigation liability. Fiscal 2026 guidance was raised, but 2027 faces rate pressures; investments in AI and quality are expected to support long-term growth.
-
Q2 2026 saw strong revenue and margin growth, with net income turning positive and adjusted EBITDA margin reaching 9.2%. Full-year guidance was raised on operational improvements, higher Medicaid rates, and successful participant reinstatements.
-
A vertically integrated platform delivers comprehensive care to complex dual-eligibles, achieving strong financial results through operational transformation, technology investments, and a focus on responsible growth. The underpenetrated market and supportive policy environment offer significant expansion opportunities, with both de novo and acquisition strategies in play.
-
Revenue grew 15% year-over-year to $236.1M, with Adjusted EBITDA more than doubling and net income turning positive. Census reached a record high, cost management improved, and FY2026 guidance was reaffirmed despite ongoing Medicaid and regulatory uncertainties.
Fiscal Year 2025
-
Panelists highlighted the need for better care coordination, simplified payment models, and trust-building in aging-in-place solutions. Technology and AI can enhance efficiency and personalization, but must be balanced with human interaction and social support. Private capital and policy changes are crucial for scaling innovative models.
-
Revenue and adjusted EBITDA grew double digits in FY2025, with margin expansion and improved clinical outcomes. FY2026 guidance anticipates continued growth, margin improvement, and headwinds from Medicaid redetermination and Medicare payment model changes.
-
Revenue rose 13% year-over-year to $218.1 million, with census up 10% and adjusted EBITDA margin improving to 4.9%. Operational transformation and in-house pharmacy integration drove cost discipline, while fiscal 2025 guidance was reaffirmed.
-
PACE delivers integrated care to frail seniors, enabling independence and cost savings for states. The organization leverages scale, technology, and insourcing to drive growth, operational efficiency, and margin expansion, with significant capacity for further growth and a positive policy outlook.
-
Fiscal Q2 revenue grew 10.6% year-over-year to $209M, with census up 10.3% and Adjusted EBITDA at $5.9M. Guidance for FY2025 is reaffirmed, with ongoing transformation focused on technology, operational efficiency, and scaling, despite one-time impairment charges and enrollment delays.
-
First quarter fiscal 2025 saw 12% revenue growth and a 500% increase in Adjusted EBITDA year-over-year, with strong census gains and improved margins. Guidance for the year was reaffirmed, and operational initiatives are driving measurable improvements despite ongoing regulatory and enrollment challenges.
Fiscal Year 2024
-
Q4 and fiscal 2024 saw double-digit revenue growth, margin expansion, and improved net loss, driven by higher enrollment and operational efficiencies. Fiscal 2025 guidance projects continued growth, with margin improvement and ongoing investments, while state enrollment delays and regulatory audits remain key uncertainties.